The two Roche towers in Basel, Switzerland, rising behind trees on the bank of the Rhine under a blue sky · HerBauhaus, via Wikimedia Commons · CC BY-SA 4.0

Article · 2026-10-24 · 2 min read · Biotechnology · Stocks

Zymeworks licenses its DLL3 lung cancer drug ZW209 to Roche

Roche takes on the drug's development costs and pays $55 million once antitrust review clears, with $40 million more at the next trial.

By the desk. Researched and written by an AI model from the sources listed at the end; nothing here restates another publication's text.

ZYME Zymeworks Inc.direct AMGN Amgen Inc.adjacent ZLAB Zai Lab Limitedadjacent

What happened

Zymeworks said on Friday 23 October that it has given Roche the exclusive worldwide rights to develop and sell ZW209, an experimental drug aimed at small cell lung cancer. ^{[1, 2]}

The agreement was signed on Thursday 22 October, Zymeworks' current report to the SEC says. Roche agreed to pay $55 million up front and $40 million when the Phase 1b trial, the second stage of early testing, begins. Zymeworks can also earn up to $718 million in research, development, commercial and sales milestones. ^{[1, 2]}

Zymeworks is also eligible for tiered royalties from the high single digits to the mid teens, in percent of net sales. In the release, Roche's head of corporate business development, Boris L. Zaïtra, called ZW209 'an innovative approach' that complements its lung cancer work. ^{[1, 2]}

Why it matters

Zymeworks filed a net loss of $81.1 million for 2025 on revenue of $106.0 million, and spent $137.0 million on research and development. Roche also takes on the cost of the drug's development, including the first trial that Zymeworks runs. ^{[3, 1]}

How the drug works

DLL3 is a protein on the surface of small cell lung cancer cells in about 85 to 96 percent of patients and is barely found on healthy cells, Amgen wrote in 2024. ZW209 is a T cell engager: an antibody that grips the tumor cell and an immune cell at once, so the immune cell kills the tumor. ^{[4, 2]}

It is trispecific, binding DLL3 and two T cell proteins, CD3 and CD28, a design Zymeworks says should strengthen the immune response. The FDA has cleared it for human testing, and a Phase 1 study in advanced solid tumors has begun, the company said. BioSpace described the drug as preclinical while reporting the same trial start. ^{[2, 5]}

What settles it next

The license takes effect only after the waiting period under the Hart Scott Rodino antitrust law ends, and the upfront payment is due after that clearance, the 8-K says. Either side may end the deal if clearance does not come by a set date, and Roche may end it at any time on notice. ^[1]

Zymeworks hosts a call on the deal on Tuesday 27 October at 8:30 a.m. Eastern time. Zai Lab's private placement of about $250 million is set to close the same day, its 8-K says. ^{[2, 6]}

Who it reaches

Zymeworks (ZYME) is direct: it licenses the drug and receives the payments. Amgen (AMGN) is adjacent: Zymeworks' annual report names its approved DLL3 drug Imdelltra as competition for ZW209. ^{[1, 3]}

Zai Lab (ZLAB) is adjacent: the same report names its DLL3 drug zocilurtatug pelitecan, and Zai Lab said on Thursday 22 October that the placement's proceeds go mainly to that drug. The annual report also lists two DLL3 programs Roche already runs with partners, Chugai and Innovent. ^{[3, 6, 7]}

Sources

Every stock is a company; the desk grades the company behind the stock. This article describes; it does not recommend. Adjacent means the company is not named in the event and the path by which it is reached is stated above.

All news →